Key Insights

Highlights

Success Rate

74% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

13.7%

14 terminated out of 102 trials

Success Rate

73.6%

-12.9% vs benchmark

Late-Stage Pipeline

9%

9 trials in Phase 3/4

Results Transparency

23%

9 of 39 completed with results

Key Signals

9 with results74% success14 terminated

Data Visualizations

Phase Distribution

49Total
Not Applicable (14)
P 1 (11)
P 2 (15)
P 3 (6)
P 4 (3)

Trial Status

Completed39
Unknown18
Recruiting15
Active Not Recruiting14
Terminated14
Withdrawn2

Trial Success Rate

73.6%

Benchmark: 86.5%

Based on 39 completed trials

Clinical Trials (102)

Showing 20 of 20 trials
NCT06965751Phase 1Active Not RecruitingPrimary

A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19

NCT07013474Phase 3RecruitingPrimary

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

NCT04169542Recruiting

Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery

NCT04569851TerminatedPrimary

Clinical Characteristics and Prognostic Factors of Patients With COVID-19 (Coronavirus Disease 2019)

NCT04387656Active Not RecruitingPrimary

NCI COVID-19 in Cancer Patients, NCCAPS Study

NCT04650178Active Not RecruitingPrimary

Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials

NCT07552779Phase 1Recruiting

A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir

NCT04474301RecruitingPrimary

Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic

NCT04565665Phase 1RecruitingPrimary

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

NCT05672355Phase 2Recruiting

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

NCT04447222Active Not RecruitingPrimary

Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors

NCT05022446RecruitingPrimary

The Impact of COVID-19 on Pulmonary Procedures

NCT04977024Phase 2Active Not RecruitingPrimary

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

NCT04639466Phase 1CompletedPrimary

A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection

NCT04491292RecruitingPrimary

Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce

NCT06381739Phase 2RecruitingPrimary

A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol

NCT04582903RecruitingPrimary

Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence

NCT04500600Active Not RecruitingPrimary

Well-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic

NCT04355533Not ApplicableCompletedPrimary

Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19

NCT05228275Active Not RecruitingPrimary

Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer

Scroll to load more

Research Network

Activity Timeline